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Abstract
By 2015, vaccine shortages still remained one of the major problems around the globe, as described in the annual
secretariat report of the Global Vaccine Action Plan (GVAP). Despite multiple initiatives to reduce vaccine shortages,
supply interruptions are unexpected and unavoidable. To mitigate the risk of such interruptions, vaccine stockpiles
have traditionally been the tool of choice. However, the models used to determine vaccine stockpile levels have only
considered the use of monovalent vaccines, which provide protection against a single disease. This study aims to
determine optimal stockpile levels for combination vaccines, which provide protection against multiple diseases. First,
through discrete event simulation, we explore the effect on antigen shortages while maintaining stockpiles of multiple
vaccines from multiple suppliers with different reliability conditions. We consider policies that mimic those of a
decision maker that can either use vaccines with the most or the least reliable supply to set up the safety stockpile.
Second, we propose a stochastic tractable safety stock model that considers the availability of a pool of monovalent
and combination vaccines in the stockpile. Finally, we contrast the recommendations from the simulation with those
from the stochastic safety stock model, and we analyze the effect of having a mix of combination and monovalent
vaccines to mitigate the shortage risks for any given antigen.
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1. Introduction
In 2010, international health organizations such as the World Health Organization (WHO), the United Nations
Children’s Fund (UNICEF), the National Institute of Allergy and Infectious Diseases (NIAID), the Bill and Melinda
Gates Foundation, and other partners collectively launched the ‘Decade of Vaccines’ collaboration program [1]. This
program includes the Global Vaccine Action Plan (GVAP) for the years 2011 to 2020, which aims to immunize every
child and woman irrespective of their location or economic condition [1]. One of the six strategic objectives of GVAP
is that every immunization program conducted in each country should have a sustainable vaccine supply [1]. In 2014,
during the annual assessment of the GVAP goals, the Strategic Advisory Group of Experts on Immunization (SAGE)
claimed that the goal of attaining target global immunization coverage rates for multiple vaccines was off track. One
of the main reasons for this was vaccine stockouts due to global supply interruptions [2].
Table 1: Global vaccine stockout details
2010

2011

2012

2013

2014

67

66

57

54

50

Number of stockout events in a year

153

148

120

111

110

Average number of stockout events per year per country

2.28

2.24

2.11

2.06

2.2

Average duration of a stockout event (in days)

45.2

35.3

34

32

52.7

Countries facing minimum one national-level stockout for at least
one vaccine

Sources: GVAP—Monitoring, Evaluation, and Accountability—Secretariat Annual Report 2015 [2].

Table 1, illustrates the number of stockout events that occurred globally between 2010 and 2014. On average 58
countries faced stockouts every year between 2010 and 2014. In 2014, out of 194 countries, 50 countries faced
national-level stockouts at least once a year [2]. Most of the countries facing stockouts were low- to middle-income
developing countries [2]. These supply interruptions have an impact on global immunization coverage rates [2], which
can cause the risk of spreading diseases that have been previously controlled.

All countries are susceptible to supply interruptions and vaccines shortages. In the U.S., over the past decade, there
was on average one pediatric vaccine interruption per year. The duration of these vaccine shortages varied widely
from three months to 22 months (see Table A [3]–[9] in the Appendix). Hence, it is reasonable to expect that the
developing countries with weaker healthcare systems than that in the U.S. may face at least as many vaccine shortages
1

with similar or lengthier duration. Evaluation of the safety stocks to mitigate vaccine shortages requires careful
consideration, as decision makers in developing countries need to balance costs and their ability to maintain safety
stocks in limited cold-chain facilities.

Most of the available literature on safety stock levels of vaccines considers safety stocks composed solely of
monovalent vaccines, which provide protection against single disease in one shot, whereas combination vaccines
provide protection against multiple diseases in one shot. Additionally, the vaccine stockpile literature does not
consider the case when there are multiple suppliers for a vaccine, while in reality UNICEF, the Global Vaccine
Alliance (GAVI), and WHO try to maintain competition among suppliers to avoid supplier monopolies in the global
vaccine markets [10], [11].

This study aims to determine the stockpile levels for combination vaccines facing uncertain supply interruptions when
multiple suppliers per vaccine are available in the market. We first develop a simulation model to mimic supply
shortages under different stockpile configurations and explore the effect of these configurations on the shortage levels
resulting from different supply interruption scenarios. Second, considering the results of the simulation study, we
propose a tractable safety stock model. We compare the recommended safety stock levels from the tractable model
with those resulting from the simulation study.

The remaining document is divided into four main sections. Section 2 provides a literature review; Section 3 details
the research question and the hypothesis of this study; and Section 4 describes the methodology, which includes
simulation study and the formulation of the proposed tractable safety stock model. Section 5 describes the validation
of the safety stock model, and finally, Section 6 provides concluding remarks and future extensions.

2. Literature Review
This section provides an overview of the different approaches used to determine the vaccine stockpile levels used to
mitigate shortages. Most of the studies reviewed focus on the safety stock levels for monovalent vaccines [8], [12]–
[14], which is inadequate as most countries use combination vaccines in their immunization schedules. However,
studies that consider combination vaccines [7], [15] fail to consider either the uncertainty in the occurrence of supply
interruption and assume that the length of the supply interruption is deterministic in nature.
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In the U.S., the pediatric vaccine stockpile maintains a rotating stock for all its recommended vaccines. By law, the
country maintains a stock to satisfy six months of the vaccine demand carried out through the Vaccines for Children
(VFC) program [15]. The six months of the VFC demand represents only three months of the national demand [16].
However, these prescriptive stockpile levels were inadequate to deal with the vaccine supply interruptions observed
during 2000 and 2012, which lasted up to 22 months [8] (see Appendix Table A for details of shortage events observed
in the U.S.).
At the global level, vaccine stockpiles are maintained by international health organizations such as WHO, UNICEF,
Médecins Sans Frontières (MSF), and the International Federation of the Red Cross (IFRC). WHO currently maintains
stockpiles for four vaccines—the smallpox, meningococcal, yellow fever, and oral cholera vaccines [17]. UNICEF
and its partners are currently developing oral polio vaccine (OPV) stockpile [18]. The decision to determine which
vaccine should be stockpiled for global use and the number of doses to be stored is made by representatives from
WHO and in some cases in combination with MSF, IFRC, and UNICEF [17],[19]. Decisions on each stockpile level
are evaluated by discussing different scenarios for each vaccine that considers various factors such as disease
characteristics, including fatality rates, frequency of observed epidemics, number of countries affected, availability of
disease detection methods, vaccine efficacy, vaccine availability, and the existence of alternative treatment methods
[17]. The stockpile levels of the vaccines maintained by WHO and its international partners are shown in Table 2.
Table 2: Vaccine stockpile doses at international health organizations
Vaccine

Establishment year

Doses

Smallpox vaccine

1980

35 million

Meningococcal vaccine

1997

9 million

Yellow fever vaccine

2001

5 million

Oral cholera vaccine

2013

6 million

Oral polio vaccine

In progress

TBD

Sources: [17], [18], [20], [21]
In 2006, Jacobson et al. [8] analytically proposed a stochastic safety stock model that minimizes the risk of a vaccine
supply shortage for monovalent vaccines in the U.S. The model identifies adequate stockpile levels for different
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vaccines, considering that supply interruptions and their lengths are random. The supply was assumed to be gradually
restored via two different ramp-up functions [8].
Proaño et al. [13] proposed a multi-attribute utility model to determine the appropriate stockpile level for monovalent
vaccines considering the need to minimize cost, maximize herd immunity, and minimize the risk of shortages. The
model determines safety stock levels that optimize utility functions for the vaccine shortages, the coverage rate, and
the financial cost savings.
Shrestha et al. [7] introduced ‘VacStockpile,’ a spread-sheet and rule-based tool, to evaluate the impact of stockpile
levels with six months of supply in the U.S. The tool suggests the number of children that will not receive the
recommended doses of vaccine for given stockpile levels, considering the likelihood of a finite set of shortage
scenarios [7]. The model also defines the cost associated with maintaining these stockpile levels considering a finite
set of monovalent and combination vaccines in stock. However, for combination vaccines, VacStockpile simply
facilitates the evaluation of all permutations of different likely shortage scenarios and does not pre-emptively provide
the stockpile levels to be maintained against random supply interruption [16].
Truong [22] derived upper and lower bounds for the target stockpile levels for monovalent and combination vaccines.
The stockpile policy given by Truong [22] is based on a marginal cost analysis approach considering non-linear
backorder cost with uncertainty in the fulfillment of placed orders. The model is then verified by observing the results
of 1,000 random instances of these scenarios. The study also shows that there is a significant decrease in stockpile
level if there is more than one supplier for any particular vaccine [22]. The holding and backorder costs vary widely
among countries, and it may not always capture the risk of supply interruptions appropriately.
Thompson and Tebbens [23] proposed a framework for optimal global stockpiles in the form of a stock and flow
diagram. The framework guides in determining the trade-offs between vaccine stockpile cost and health benefits
considering the vaccine stockpile to be used during the emergency response to a disease outbreak [23]. The framework
also highlights the need for improving global vaccine supply efficiency to ensure an adequate vaccines supply and
provides recommendations for universal vaccines (vaccines having large global demand) and non-universal vaccines
(new and niche vaccines) [23]. It does not propose a tractable model to determine the optimal stockpile levels and also
does not consider the existence of multiple vaccines providing similar antigens that can satisfy the demand of antigens.

4

3. Research Question
In this study we aim to determine what the optimal stockpile level should be for vaccine safety stocks that contain
combination vaccines to mitigate the risk of uncertain supply interruptions while considering the presence of multiple
suppliers having different likelihoods of supply interruptions. We also aim to determine the impact on safety stockpile
levels of choosing to stock vaccines with a high risk of supply interruptions versus using vaccines with a low risk of
supply interruptions. Without loss of generality, we refer to the first alternative as the policy of stockpiling risky
vaccines and to the second as the policy of stockpiling robust vaccines.
To achieve the aforementioned objectives, we apply our proposed methodology to the experimental scenarios designed
to consider the needs of low-income (LI) and lower-middle-income (LMI) countries served by the WHO African
region, which has suffered frequent supply interruptions, as observed in the 2015 GVAP secretariat report
[2],[24],[25]. In particular, we focus on the safety stock of vaccines offering the diphtheria-tetanus-pertussis (DTP),
haemophilus influenzae type B (Hib) and hepatitis B (HepB) antigens. Such vaccines include monovalent vaccines—
DTwP, Hib, and HepB—and the combination vaccine DTwP-Hib-HepB, usually referred as the pentavalent or penta
vaccine.

4. Methodology
We approach the research problem by first understanding the trends in supply shortage levels of a vaccine as a result
of changes in the market conditions through a simulation study. We then apply that which was learned from the
simulation study to develop a prescriptive tractable safety stock model. Section 4.1 explains the simulation study in
detail, while section 4.2 details the tractable safety stock model.
4.1 Simulation Study
We propose a discrete simulation model to mimic different shortage scenarios by considering multiple input factors.
This simulation model is used within an experimental design to test the effect of the following factors: (1) the number
of vaccine suppliers, (2) the probability of supply interruption for these suppliers, (3) the length of the supply
interruption, and (4) the choice of stockpiling policy (i.e., using risky vaccines vs. robust vaccines). In section 4.1, we
will first describe the overview of the proposed simulation model and then explain in further detail the structure of the
experimental design along with the set of assumptions considered in our experimentation as well as in the tractable
model proposed in section 4.2.
5

4.1.1 Simulation Model
The simulation model mimics the shortage scenarios based on the different inputs and determines the expected
shortage levels for each of the vaccines constituting the safety stock. The simulation model evaluates shortage levels
that could happen over a planning horizon of one year for randomly generated instances of supply interruptions. The
simulation assumes that the impact of a vaccine supply interruption can be mitigated by the use of alternative vaccines
(some of them being combination vaccines) that provide some or all of the antigens missing due to the vaccine
shortage. The simulation model consists of two random events: one that determines whether a vaccine will face a
supply interruption and, if so, the random length of such interruption.
Figure 1 illustrates the flow of this simulation model. First, the model randomly determines which vaccine supplier
will undergo a supply interruption based on their probability of having a supply interruption. Then, the model
randomly determines the length of such interruption based on a given distribution. Then, the shortage level for all the
antigens provided by the vaccine facing a supply interruption is determined. The resulting deficit of the number of
antigens serves as a proxy of the expected antigen shortage, which is satisfied by all the vaccines in the safety stock
that can supply the antigen of the vaccine in shortage.
The study is conducted using birth cohorts and the immunization schedules of 28 LI and LMI countries in WHO’s
African region (see Appendix Table B) [24],[25]. The vaccine immunization schedules were obtained from the ‘WHO
Vaccine-preventable Diseases: Monitoring System, 2016’ [26], and the annual birth cohorts for the countries were
obtained from the ‘UNPD Population and Demographic Data Estimates (Medium Variant), 2015’ [27].
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INPUT

PROCESS

• Sets of
antigens,
vaccines and
suppliers
• Probability of
interruption
at suppliers
• Annual birth
cohorts of the
countries
• Interruption
length
distribution
parameters
• Production
capacity of
each supplier

OUTPUT

For all scenarios

For every instance

Randomly
select a
vaccine
supplier to
face supply
interruption

Identify 𝜑𝑣𝑎

Randomly
generate
length of
supply
interruption

Identify
shortage
levels for
each antigen
in the vaccine

Estimate vaccine
shortage levels
Max {𝜑𝑣𝑎 .
Shortage level of
each antigen}

Map the
expected
shortage
levels to the
minimum
stockpile
level of each
vaccine

𝜑𝑣𝑎 = Proportion of antigen ‘a’ demand satisfied by vaccine ‘v’
Figure 1: Simulation model process flow chart

As described in Figure 1, the model inputs include the set of vaccines, the set of antigens supplied by those vaccines,
the set of suppliers of each vaccine, the probability of interruption at each supplier, the distribution of the interruption
length, and production capacities. The inputs are provided to a model based on the experimental scenario that we want
to test. Each experimental scenario is replicated 1,000 times. We assume that if there are 𝑛 vaccines supplying antigen
𝑎 and each vaccine has 𝑚 suppliers, then the total production from these suppliers is equal to the total requirement of
antigen 𝑎 in the market. Only in cases when there are only combination vaccines in the market and some of the antigens
contained in the vaccine have a higher number of recommended doses than remaining antigens, it is possible to have
some surplus for the antigens with lower dose requirements. We assume that both combination vaccines and
monovalent vaccines are offered in the market, yet a major portion of antigen demand is satisfied via combination
vaccines.
For a vaccine 𝑣 supplying a set of antigens 𝑎𝑣 , the simulation first determines whether there will be a supply
interruption at any of its suppliers based on their probability of interruption, which is assumed to be independent from
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the probabilities of interruption for other suppliers. Then, a second random event takes place that determines the length
of the supply interruption (in days) for those vaccine suppliers. Interruption length accounts for the time from the
beginning of the supply interruption until that supplier is back to full production, and during this interval the production
from the supplier is assumed to be completely halted—that is, no partial production levels are considered in this study.
It is assumed that the length of an interruption follows a known distribution, whose parameters are provided as inputs
to the model and can be varied based on the experimental scenario that we test. A truncated normal distribution is
considered as a preliminary choice to explore the effect of interruption length on shortage levels. A lead time of seven
days is assumed necessary to account for shipping the vaccines from the supplier to the final destination once the
random interruption is over.
After the random interruption length is determined, the model quantifies the shortage levels for each antigen 𝑎𝑣
resulting from the vaccine in shortage. The shortage level is identified by mapping the unmet antigen needs of the
population over the period of interruption. The unmet antigen need is determined by comparing the antigen demand
versus the supply provided by all vaccines containing that antigen during the supply interruption. The antigen demand
is computed from the daily number of births in the population and number of antigen needed per child to be fully
immunized. The notation described below and equation (1) provide the mathematical representation of antigen
demand during the interruption period.
Let,
𝐴: Set of antigens
𝑉: Set of vaccines articulated to supply all the antigens
𝑆: Set of vaccine suppliers
𝑆𝑣 : Set of suppliers for vaccine 𝑣 ∈ 𝑉. 𝑆𝑣 ⊂ 𝑆
𝑉𝑎 : Set of vaccines containing antigen 𝑎 ∈ 𝐴. 𝑉𝑎 ⊂ 𝑉
𝐴𝑣 : Set of antigens supplied by vaccine 𝑣 ∈ 𝑉. 𝐴𝑣 ⊂ 𝐴
𝐿: Length of supply interruption in days.
𝑑𝑎 : Daily demand of antigen 𝑎 ∈ 𝐴 doses.
𝐶𝑠𝑣 : Daily supply of vaccine 𝑣 ∈ 𝑉 produced by supplier s ∈ 𝑆
𝑁𝑎 : Need of antigen 𝑎 ∈ 𝐴 during interruption period.
𝑚𝑣 : Number of suppliers of vaccine 𝑣 ∈ 𝑉.
𝑝𝑣 : Probability of interruption for suppliers of vaccine 𝑣 ∈ 𝑉.
𝑊𝑣𝑎 : Relative importance of vaccine 𝑣 ∈ 𝑉 with respect to supply of antigen 𝑎 ∈ 𝐴.
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𝑆𝑢𝑝𝑣 : Total supply of vaccine 𝑣 ∈ 𝑉 per day.
𝐼𝑣 : Supply shortage level of vaccine 𝑣 ∈ 𝑉.

When there is a supply interruption at supplier 𝑠𝑣 , then supply per day of the vaccine from that supplier 𝐶𝑠𝑣 is stopped
for the length of the supply interruption. Therefore, the need for antigen 𝑎 across the population during the supply
interruption of vaccine 𝑣 is given by

𝑁𝑎 = 𝐿 ∗ 𝑑𝑎 − ∑ 𝐶𝑠𝑣
(

𝑠 ∈ 𝑆𝑣
𝑣 ∈ 𝑉𝑎

∀𝑎 ∈ 𝐴 .

(1)

)

The expected shortage level of each vaccine is determined such that the antigen need of each antigen a identified in
(1) is fulfilled completely by the vaccines 𝑣𝑎 containing antigen a, which may be provided by different suppliers.
Considering that the proportion of demand for antigen a supplied by vaccine v is expressed as φ𝑣𝑎 , then the antigen
needs 𝑁𝑎 for antigen a when a vaccine is in shortage is fulfilled by all other vaccines supplying that antigen in the
proportion given by 𝜑𝑣𝑎 . Thus, for a vaccine that contains multiple antigens, the expected vaccine shortage level 𝐼𝑣 is
defined as the maximum of the number of doses required to fulfill the need for the antigen supplied by that vaccine.
𝐼𝑣 = 𝑚𝑎𝑥(𝑁𝑎 ∗ 𝜑𝑣𝑎 |𝑎 ∈ 𝐴𝑣 )

∀𝑣 ∈𝑉

(2)

The ratio φ𝑣𝑎 is estimated by the relative importance 𝑊𝑣𝑎 of the vaccine v toward the safety stock with respect to the
overall relative importance of all other vaccines supplying antigen a, as shown in (3).

𝜑𝑣𝑎 =

𝑊𝑣𝑎
∑𝑣 ∈ 𝑉𝑎 𝑊𝑣𝑎

∀ 𝑣 ∈ 𝑉 𝑎𝑛𝑑 𝑎 ∈ 𝐴

(3)

The relative importance of vaccine 𝑣 for the supply of antigen 𝑎 (𝑊𝑣𝑎 ) is higher as the supply of 𝑣 (𝑆𝑢𝑝𝑣 ) is high with
respect to the antigen demand 𝑑𝑎 . Also, it is higher as the number of suppliers for 𝑣 (𝑚𝑣 ) decreases. Whereas As the
probability of interruption 𝑝𝑣 is high, 𝑊𝑣𝑎 is higher in case of policy to stockpile risky vaccines but it decreases in
case of policy to stockpile robust vaccines. The expression (4) is used for the policy that stockpiles risky vaccines
because here 𝑊𝑣𝑎 is directly proportional to the average probability of having a supply interruption. Hence, the relative
importance of vaccines for the supply of antigen ‘𝑎’ increases as their likelihood of having a supply interruption
increases. Equation (5) is used for the second policy to stockpile robust vaccines since it considers that 𝑊𝑣𝑎 is directly
proportional to the probability of not having an interruption at the vaccine supplier. Hence, the relative importance of
9

vaccines for the supply of antigen ‘𝑎’ increases as their likelihood of having supply interruptions decreases.
(𝑆𝑢𝑝𝑣 )⁄
𝑚𝑣
𝑊𝑣𝑎 = (
) ∗ 𝑝𝑣
𝑑𝑎
(𝑆𝑢𝑝𝑣 )⁄
𝑚𝑣
𝑊𝑣𝑎 = (
) ∗ (1 − 𝑝𝑣 )
𝑑𝑎

∀ 𝑣 ∈ 𝑉 𝑎𝑛𝑑 𝑎 ∈ 𝐴

∀ 𝑣 ∈ 𝑉 𝑎𝑛𝑑 𝑎 ∈ 𝐴

(4)

(5)

4.1.2 Experimental Design
The simulation model described in section 4.1.1 serves as a tool for conducting experiments over scenarios of interest.
We consider the set of vaccines that contains antigens for DTP that are part of the immunization schedule of the 28
LI and LMI African countries. According to the 2015 GVAP secretariat report [28], DTP-containing vaccines have
faced frequent shortages. We assume that the DTP-containing combination vaccine DTwP-Hib-HepB, also called a
pentavalent vaccine, is available in the market along with the three monovalent vaccines DTwP, Hib, and HepB
(monovalent vaccines with antigens for DTP, Hib, and HepB, respectively).
We test two stockpiling policies: policy (A)—stockpiling risky vaccines that are prone to supply interruptions and
policy (B)—stockpiling robust vaccines that suffer fewer supply interruptions (i.e., that are robust to interruptions).
When we have both monovalent and combination vaccines in the market, for a given antigen, the shortage level will
be fulfilled by a safety stock containing both types of vaccines. Based on the experimental combinations, each of these
vaccine types may have higher or lower probabilities of interruption. So, two different stockpiling policies are tested,
first in which the larger fraction of the antigen shortage is fulfilled by the stockpile of vaccines with a higher probability
of interruption and second where stockpiling policy satisfies a larger portion of antigen shortage by stockpiling
vaccines with a lower probability of interruption. To determine the aforementioned fraction of antigen demand
satisfied by each type of vaccine, 𝜑𝑣𝑎 from (3) is used. Then, to mimic policy A we use expression (4) for 𝑊𝑣𝑎 , while
expression (5) is used to mimic policy B. We use 2𝑘 factorial design to test the effect of the parameters related to these
four vaccines on their expected shortage levels.
We conduct three sets of experiments. Experiment 1 considers that we have both combination and monovalent
vaccines in the market and that the safety stockpile also contains both combination and monovalent vaccines. Some
portion of the antigen shortage level is satisfied by combination vaccines, while the remaining portion is satisfied by
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monovalent vaccines. This portion varies depending upon whether stockpiling policy A or B is used for determining
stockpile levels. It also depends on the number of vaccine suppliers and their production capacities. In experiment 2,
we consider that the market has only monovalent vaccines and that these vaccines are the only ones used for the
stockpile. Hence, for a given antigen during an interruption, its supply is fulfilled by only monovalent vaccines.
Stockpiling policies A and B do not play any role as we do not have any alternative combination vaccine in the
stockpile to share the antigen shortage level. For experiment 3, it is considered that the stockpile includes only
combination vaccines. Even in this experiment stockpiling policies do not play any role as the entire antigen shortage
during the supply interruption is satisfied by only combination vaccines in the stockpile. Experiments 2 and 3 aim to
facilitate comparing the expected shortage levels of vaccines when we have only monovalent vaccines in the safety
stock or only combination vaccines or a mix of combination and monovalent vaccines.
Certain assumptions are needed to support our analysis. It is assumed that for a given vaccine all its suppliers have the
same probability of interruption. Also, we assume that for a vaccine, each of its suppliers has equal production
capacity. For a given antigen, the total supply of all vaccines containing the antigen is enough to satisfy the
uninterrupted antigen demand and yet there is no excess vaccine supply for a given antigen in the market. However,
for experiment 3, since there is only pentavalent vaccine in the market to satisfy all antigens’ demand and each antigen
has different dosage requirements, we allow the over-production of Hib and HepB antigens which require fewer doses
than the DTP antigen. For experiment 1, when we have both monovalent and combination vaccines together in the
market, it is assumed that a major portion (60–70%) of the antigen demand in the market is supplied by the
combination vaccine.
Next, we describe the actual set up for each of the three experiments. We explain how the four factors that we seek to
control—that is, the number of vaccine suppliers, the probability of interruption, the mean interruption length, and the
stockpiling policy—have been incorporated into each of the three experiments.
4.1.2.1 Experiment 1
In this experiment, we propose a 210 -factorial design resulting from the study of how our four factors of interest affect
the safety stockpile of each of the four vaccines, DTwP, DTwP-Hib-HepB (penta), Hib, and HepB. The factors
considered in this experiment are a number of suppliers for each vaccine, the probability of interruption at each
vaccine’s suppliers, the mean interruption length, and stockpiling policy. Table 3 describes the levels for each factor
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used in this experiment. The 210 -factorial design results in 1,024 experimental scenarios. Each experimental scenario
is replicated 1,000 times to generate 1,024,000 random instances of supply interruptions.
Table 3: Factors used in experiment 1
No.

Factors

Level 1

Level 2

Number of suppliers of vaccines
1

Number of DTwP suppliers

1

7

2

Number of DTwP-Hib-HepB suppliers

1

7

3

Number of Hib suppliers

1

7

4

Number of HepB suppliers

1

7

Probability of interruption at suppliers
5

DTwP suppliers’ probability of interruption

0.06

0.2

6

DTwP-Hib-HepB suppliers’ probability of interruption

0.06

0.2

7

Hib suppliers’ probability of interruption

0.06

0.2

8

HepB suppliers’ probability of interruption

0.06

0.2

150

360

A

B

Interruption length
9

Mean interruption length (days)

Stockpiling policy
10

Stockpiling policy

The probability of interruption values for each level shown in Table 3 corresponds to the probability of vaccine supply
interruption over a period of one year. These probabilities are estimated for one year considering that the supply
interruption happens once in five years (as level 2) or once in 15 years (as level 1). These derived values correspond
to 0.2 and 0.06 factor levels for the probability of supply interruption, respectively. From 1985 to 2000 (a period of
15 years), there was no major supply interruption observed in the U.S. [29], while from 2000 onwards to 2012 frequent
shortage events are observed, as listed in Table A in the Appendix. Thus, the lower factor level for the probability of
interruption is considered as a supply interruption occurring once in 15 years.
UNICEF, GAVI, and WHO have worked toward increasing the number of vaccine suppliers in the global market and
avoiding a monopoly by any single supplier. Due to these efforts, DTP-containing vaccines on an average have six

12

WHO-qualified suppliers in the global market [30]. Hence, a high factor level for the number of suppliers for each
vaccine is considered to be seven.
From the 2015 GVAP annual secretariat report [2] and the data shown in Table 1 in the introduction section, it can be
seen that the average duration of a stockout was at least two months for 2010–2014. These stockouts are reported
when the safety stock for a three-months’ supply is depleted [2]. Hence, we can assume that a supply interruption can
last for at least five months. However, from the shortages reported in the U.S. in early 2000 (refer Appendix Table
A), we see that the supply interruptions lasted for more than a year on average. As we are considering a time horizon
of one year for the simulation instance, we assume that the maximum interruption over a year can be 12 months (360
days).
4.1.2.2 Experiment 2
In this experimental set, we consider that the safety stock relies exclusively on three monovalent vaccines, DTwP,
Hib, and HepB. The experimental factors in this experiment are the number of suppliers for each vaccine, the
probability of interruption at each vaccine’s suppliers, and mean interruption length. The list of factors under
consideration and the factor levels are given in Table 4. The resulting 27 -factorial design is used, which results in 128
experimental scenarios. Each scenario is also replicated 1,000 times in the simulation model, giving 128,000 instances
of supply interruption. The assumptions and the selection of the factor levels are justified similarly as that for
experiment 1.
Table 4: Factor levels for experiment 2
No.

Factors

Level 1

Level 2

Number of suppliers of vaccines
1

Number of DTwP suppliers

1

7

2

Number of Hib suppliers

1

7

3

Number of HepB suppliers

1

7

Probability of interruption at suppliers
4

DTwP suppliers’ probability of interruption

0.06

0.2

5

Hib suppliers’ probability of
interruption

0.06

0.2

13

6

HepB suppliers’ probability of interruption

0.06

0.2

150

360

Interruption length
7

Mean interruption length (days)

4.1.2.3 Experiment 3
In this experiment, we consider that only the pentavalent combination vaccine (DTwP-Hib-HepB) is available in the
market and its safety stock to fulfill any antigen’s demand from a supply interruption of the pentavalent vaccine. Table
5 shows the factors considered for this experiment and their experimental levels. Here, a 23 -factorial design is used,
resulting in eight experimental scenarios replicated 1,000 times, and thus we have 8,000 instances of supply
interruption.
Table 5: Factors used in experiment 3
No.

Factors

Level 1

Level 2

1

7

0.06

0.2

150

360

Number of suppliers
1

Number of DTwP-Hib-HepB suppliers

Probability of interruption at suppliers
2

DTwP-Hib-HepB suppliers’ probability of interruption

Interruption length
3

Mean interruption length (days)

4.1.3 Results
We aim to determine whether there are any significant effects of the key factors on the expected shortage and shortage
variance for each vaccine under consideration. The expected shortage for a given experimental scenario is computed
as the mean shortage level across all 1,000 replications of that scenario, and the variance of the shortage for that
experimental scenario is the variance of the shortage levels across the same 1,000 replications. Also, the analysis is
performed to determine if there are any differences in expected shortage levels and the costs across experiments 1, 2,
and 3.
Experiment 1 includes both combination and monovalent vaccines in the stockpile. We analyze the expected shortage
of the individual vaccines as well as expected shortages across all vaccines in the safety stock. Figure 2 illustrates the
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main effects of all factors on the expected shortage across all vaccines. It can be seen that as the number of suppliers
for each monovalent vaccine increases, the total shortage across all the vaccines decreases. However, as the number
of suppliers for the penta vaccine increases, there seems to be an increase in the total expected shortage levels. On the
other hand, if there is an increase in the probability of interruption at any vaccine supplier, the total expected shortage
level increases. Similar is the effect of interruption length. As the mean interruption length increases, the total expected
shortage also increases. However, the effect of choice of stockpiling policy on the total expected shortage does not
seem to be significant.
Figure 4 shows the main effects plot of the key factors on the expected shortage levels of the individual vaccines. It
can be seen that when the number of suppliers of the vaccine under consideration increases, there is a decrease in the
expected shortage level. However, if the number of suppliers of a vaccine containing at least one similar antigen
increases, there seems to be an increase in the expected shortage level, whereas with the increase in the probability of
interruption and the mean interruption length, the expected shortage of all the vaccines increases. Also, there is no
effect of a change in stockpiling policy A or B on any of the vaccine’s expected shortage levels. Additionally, multiple
two-level interactions of the factors seem to have a significant effect on the expected shortage levels of the vaccine,
such as number of vaccine suppliers and interruption length, number of vaccine suppliers and probability of
interruption for the same vaccine suppliers, and number of suppliers of the vaccine under consideration and number
of suppliers of a vaccine supplying similar antigens to those of the vaccine under consideration. Interaction plots for
total expected shortage and each of the individual vaccine shortages is shown in Appendix figures A3 and A4.
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Figure 2: Experiment 1—Main effects of factors on total stockpile levels

Figure 3: Experiment 1—Main effects of factors on variance of total shortage levels
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Figure 4: Experiment 1—Main effects of factors on individual vaccine expected shortage levels

Figure 5: Experiment 1—Main effects of factors on individual vaccine variance of shortage
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We also analyzed the variance of individual vaccine shortage and the variance of shortage across all vaccines. Figure
3 represents the main effects of factors on the variance of total shortage levels. As the number of suppliers of a vaccine
increases, the total variance of the shortage across all vaccines decreases. Figure 5 shows a variance of an individual
vaccine shortage. It can be seen that as the number of suppliers of the vaccine under consideration increases, there is
a decrease in the variance of shortage. However, with an increase in the number of suppliers of vaccines containing at
least one similar antigen, there seems to be an increase in the variance of a shortage of the vaccine under consideration.
For all the vaccines, as the probability of interruption and the mean interruption length increase, there is an increase
in the variance of the vaccine shortage levels. There is no significant effect of stockpiling policy A or B on the variance
of any vaccine shortage levels. There are, however, significant two-level interaction effects, which are shown in the
figures A5 and A6 in the Appendix.
Next, we compare the results from all the three experiments—experiment 1 considering stockpiles of both combination
and monovalent vaccines, experiment 2 considering of only monovalent vaccines, and experiment 3 considering only
combination vaccines. We compare the expected shortage levels, the variance of the shortage levels, the expected
shortage cost, and the variance of the shortage cost for the three experiments. Specifically, we test the following null
and alternate hypotheses:
Null Hypothesis: 𝐻𝑜1 = Mean expected shortage levels are equal for all three experiments
Alternate Hypothesis: 𝐻𝑎1 = Mean expected shortage level for at least one experiment is not equal
Null Hypothesis: 𝐻𝑜2 = Mean variance of the shortage is equal for all three experiments
Alternate Hypothesis: 𝐻𝑎2 = Mean variance of the shortage for at least one experiment is not equal
Null Hypothesis: 𝐻𝑜3 = Mean expected cost of shortage is equal for all three experiments
Alternate Hypothesis: 𝐻𝑎3 = Mean expected cost of shortage for at least one experiment is not equal
Null Hypothesis: 𝐻𝑜4 = Mean variance of shortage cost is equal for all three experiments
Alternate Hypothesis: 𝐻𝑎4 = Mean variance of shortage cost for at least one experiment is not equal
We compare the shortage levels from the different experiments because countries have limited space in their coldchain facilities, and knowing whether to stock combination and monovalent vaccines or just consider monovalent
vaccines for safety stock affects the supply chain. Secondly, we also focus on comparing purchasing costs of vaccines
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for the expected shortage levels because a low cost will increase the affordability of the stockpiles for each country.
The vaccine prices used in this study are shown in Table 6, which are the weighted average prices (WAP) for the year
2015 obtained from UNICEF [31],[32]. Generally, it can be seen that monovalent vaccines are less expensive than
combination vaccines. The Hib vaccine is an exception in our case. Considering these vaccine price conditions, we
would like to explore the optimal type of vaccine mix that would require the minimum cold-chain space as well as the
minimum purchasing cost of vaccines in the stockpile.
Table 6: Weighted average price (WAP) per dose for vaccines under study
Vaccine
Price per dose (USD)

DTwP

Penta

Hib

HepB

0.28

1.91

4.00

0.18

Source: [31],[32]
The box plot of the expected shortage levels, the variance of such shortages, the expected shortage costs, and variance
of the shortage cost, respectively, for experiments 1, 2, and 3 are shown in Figure 6. We verify the null and alternate
hypotheses stated above by using a 2-sample t-test. The confidence interval of the difference and the p-values obtained
from the statistical tests for shortage levels are shown in Table 7, and in Table 8 shortage costs and variance are shown.
It can be seen here that experiment 3 offers the least expected shortage levels, while experiment 2 results in the highest
expected shortage levels. Also, the variance of shortage levels is largest for experiment 2, while for experiments 1 and
3, the variance is similar to each other. Given this, it is preferred not to use only monovalent vaccine stockpiles. When
we compare the expected costs of shortage, it can be seen that all three experiments have similar expense levels.
However, the variance of the shortage cost is higher for experiment 2. Thus, for the price per dose of vaccines used in
this study, which are the actual prices of the four vaccines [31],[32], having only monovalent vaccines results in the
highest purchasing cost.
Table 7: Confidence interval (CI) of difference and p-values for expected and variance of shortage levels
Expected Shortage Level

Expt
1
Expt
2

CI (Row - Col)
106 Doses
P-values
CI (Row - Col)
106 Doses
P-values

Variance of Shortage

Expt 2

Expt 3

(-4.64, -1.49)

(1.51, 10.74)

0.000

0.016

NA

(4.50, 13.88)
0.002

Expt 2
CI (Row - Col)
1012 Doses2
P-values

(-438.8, 245.7)
0.000

CI (Row - Col)
1012 Doses2
P-values

NA

Expt 3
(-275, 344)
0.798
(57, 697)
0.026
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Expected Shortage levels

Variance of Shortage levels
2000

30

20
16.6085
13.5441

10
7.41957

Variance of Shortage (10^12) (Doses^2)

Expected Shortage Level (10^6 Doses)

40

1500

1000

664.972

500
322.696

287.867

0

0
Expt-1

Expt-2

Expt-3

Expt-1

Experiment

Expt-2

Expt-3

Experiment

Expected Cost of Shortage

Variance of Shortage Cost

60

45

30

20.5892

20.44

15

14.1714

Cost Variance (10^14) (USD^2)

Expected Cost (10^6 USD)

40

30
27.4904

20

10

10.5017
8.10051

0

0
Expt-1

Expt-2

Expt-3

Experiment

Expt-1

Expt-2

Expt-3

Experiment

Figure 6: Box plot showing comparisons of each experiment type
Table 8: Confidence interval (CI) of difference and p-values for expected shortage cost and its variance

Expt
1
Expt
2

Expected Cost of Shortage
Expt 2
Expt 3
CI (Row - Col)
(-2.65, 2.95)
(-2.38, 15.21)
106 USD
P-values
0.916
0.128
CI (Row - Col)
(-2.78, 15.32)
106 USD
NA
P-values
0.149

Variance of Shortage Cost
Expt 2
Expt 3
CI (Row - Col)
(-25.33, -13.45) (-13.68, 8.87)
1012 USD2
P-values
0.000
0.630
CI (Row - Col)
(4.85, 29.13)
1012 USD2
NA
P-values
0.010

4.1.4 Simulation Study Summary
The simulation study shows that if we consider only expected shortage levels for the vaccine stockpiles, we leave a
substantial amount of risk uncovered since the variance of a shortage is large. Therefore, stockpile levels should be
determined by taking into account the variance of shortage levels as well. There is a significant effect of the key factors
on the expected shortage levels and the variances. The expected shortages and the variances decrease when the number
of suppliers of the vaccine under consideration increases. However, the expected shortage levels and their variance
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increase when the probability of interruption and the mean interruption length increase. Stockpiling policies of
stocking either risky or robust vaccines do not have any significant effect on the expected shortage levels or the
variance of shortage. Also, it is not recommended to have only monovalent vaccines in the stockpile as it would incur
a high expected shortage and high shortage variances. For the price conditions considered in this study, the expected
shortage cost is highest when we have only monovalent vaccines in the stockpile.
4.2 Tractable Model
The need to allow those responsible for vaccine inventories across the globe to easily analyze and control their safety
stock results in the need for tractable safety stock model that can be embedded in spreadsheets and can be easily used
by policy makers without having to run the simulation. Furthermore, tractable safety stock models facilitate sensitivity
analysis. Thereby we propose a tractable safety stock model assuming that it could be used as part of a continuous
review stochastic inventory system such as (𝑅𝑣 , 𝑄𝑣 ) for each vaccine 𝑣.
Without loss of generality consider that 𝑅𝑣 corresponds to the re-order inventory level that triggers an order of size
𝑄𝑣 to be placed. 𝑆𝑆𝑣 is the safety stock of vaccine 𝑣 𝜖 𝑉. 𝐼𝑙 is the random interruption length for the supply of given
vaccine 𝑣. 𝑙 is a constant for the delivery time of vaccines from the manufacturer to its destination.
When the inventory level reaches a re-order point 𝑅𝑣 for a vaccine, a fixed order quantity 𝑄𝑣 is placed during the
regular supply of vaccines. The inventory satisfies the expected lead-time demand during the time between placing
the order up to its receipt. In some cases, if the order arrives late due to any given reason, the safety stock can be used
for mitigating the shortage. However, when the supply interruption of random length 𝐼𝑙 occurs, the vaccines will be
supplied from the safety stock until the suppliers are back to full production. Thus, the focus of this study is to
determine the safety stock 𝑆𝑆𝑣 of vaccines, while determining the order quantity 𝑄𝑣 is not in the scope of this study.
It is assumed that when a supply interruption occurs for a given vaccine, the stockpile is determined for all the vaccines
supplying antigens similar to the vaccine in shortage such that their stockpiles together satisfy the expected antigen
shortages. Thus, the 𝑆𝑆𝑣 shown in Figure 6 represents the safety stock of vaccine 𝑣 when a supply interruption for the
same vaccine 𝑣 or any of the vaccines supplying similar antigens has occurred.
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𝑄𝑣

Consumption rate

𝑅𝑣

𝑆𝑆𝑣

(𝑙 + 𝐼𝑙 )
Beginning of
interruption
Figure 7: Continuous review stochastic inventory model for vaccine stockpiles

We consider that there are 𝑚𝑣 suppliers for each vaccine with the probability of supply interruption as 𝑝𝑣 . It is the
same for all the suppliers of a given vaccine. For a given vaccine, any number of suppliers 𝑁𝑣 out of the available 𝑚𝑣
can face a supply interruption. Thus, 𝑁𝑣 can take discrete values ranging from 0 to 𝑚𝑣 , where all suppliers for a given
vaccine have an equal probability of facing supply interruption 𝑝𝑣 . Therefore, 𝑁𝑣 is binomially distributed with
parameters 𝑁𝑣 ~ 𝐵(𝑚𝑣 , 𝑝𝑣 ). The interruption length 𝐼𝑙 is also considered as a random variable with known distribution
parameters. Additionally, the safety stock must offer a service level of 𝛼 so that the probability that a stockout will
not happen during the supply interruption lead-time is 𝛼%. The interruption lead-time consists of a constant time 𝑙 to
distribute vaccines to the destination in addition to the random interruption length 𝐼𝑙 .
4.2.1 Formulation of Safety Stock Model
Let us consider following notations for the sets, the parameters, and the variables.
Sets:
𝐴: Set of antigens
𝑉: Set of vaccines
𝐴𝑣 : Set of antigens supplied by vaccine 𝑣 𝜖 𝑉, 𝐴𝑣 ⊂ 𝐴
𝑉𝑎 : Set of vaccines supplying antigen 𝑎 𝜖 𝐴, 𝑉𝑎 ⊂ 𝑉
Parameters:
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𝑆𝑢𝑝𝑣 : Total supply of vaccine 𝑣 𝜖 𝑉 per day across all suppliers
𝑚𝑣 : Number of suppliers of vaccine 𝑣 𝜖 𝑉
𝑝𝑣 : Probability of supply interruption at suppliers of vaccine 𝑣 𝜖 𝑉
𝜑𝑣𝑎 : Fraction of antigen 𝑎 𝜖 𝐴 demand supplied by vaccine 𝑣 𝜖 𝑉
𝑙 : Constant for the delivery time of vaccines from manufacturer to destination once supply is restored
Variables:
𝐼𝑙 : 𝑟. 𝑣 Interruption length following a known distribution with mean 𝜇𝐼𝑙 and standard deviation 𝜎𝐼𝑙
𝑁𝑣 : 𝑟. 𝑣 Number of suppliers of vaccine 𝑣 𝜖 𝑉 out of 𝑚𝑣 facing supply interruption over a year. Given that
probability of interruption at vaccine supplier is 𝑝𝑣 , hence, 𝑁𝑣 ~𝐵(𝑚𝑣 , 𝑝𝑣 )
𝐸[𝑁𝑣 ]: 𝑚𝑣 𝑝𝑣
𝑉[𝑁𝑣 ]: 𝑚𝑣 𝑝𝑣 (1 − 𝑝𝑣 )
𝐾𝑣 : 𝑟. 𝑣 Supply shortage levels of vaccine 𝑣 𝜖 𝑉 when vaccine 𝑣 faces supply interruption
𝐷𝑎 : 𝑟. 𝑣 Lead-time demand for antigen 𝑎 𝜖 𝐴 across all vaccines facing interruption
𝐷𝑣 : 𝑟. 𝑣 Lead-time demand for vaccine 𝑣 𝜖 𝑉 due to any common antigen supplying vaccines facing interruption
In the first step, we determine 𝐾𝑣 the supply shortage of vaccine 𝑣 that is itself facing a supply interruption of length
(𝑙 + 𝐼𝑙 ). 𝐾𝑣 is a product of total supply of vaccine 𝑣 per day per supplier, the number of suppliers facing supply
interruption, and the lead-time.

𝐾𝑣 =

𝑆𝑢𝑝𝑣
. 𝑁𝑣 . (𝑙 + 𝐼𝑙 )
𝑚𝑣

(6)

As 𝑁𝑣 and 𝐼𝑙 are random variables, the expected supply shortage and its variance for a vaccine 𝑣 facing supply
interruption correspond to (7) and (8), respectively [33],[34].

𝐸[𝐾𝑣 ] = 𝐸 [

𝑆𝑢𝑝𝑣
𝑁 (𝑙 + 𝐼𝑙 )]
𝑚𝑣 𝑣

𝑆𝑢𝑝𝑣
= 𝐸[
𝑁 ] . 𝐸[(𝑙 + 𝐼𝑙 )]
𝑚𝑣 𝑣
as
𝑆𝑢𝑝𝑣
𝑆𝑢𝑝𝑣
𝐸[
𝑁𝑣 ] =
. 𝐸[𝑁𝑣 ] ,
𝑚𝑣
𝑚𝑣
and
𝐸[𝑙 + 𝐼𝑙 ] = 𝑙 + 𝐸[𝐼𝑙 ] ,
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then
𝐸[𝐾𝑣 ] =

𝑆𝑢𝑝𝑣
. 𝐸[𝑁𝑣 ]. (𝑙 + 𝐸[𝐼𝑙 ]) .
𝑚𝑣

(7)

Variance of 𝐾𝑣 is given by
𝑆𝑢𝑝𝑣
𝑉[𝐾𝑣 ] = 𝑉 [
𝑁 (𝑙 + 𝐼𝑙 )]
𝑚𝑣 𝑣
𝑆𝑢𝑝𝑣2
𝑉[𝐾𝑣 ] =
. 𝑉[𝑁𝑣 . (𝑙 + 𝐼𝑙 )]
𝑚𝑣2
𝑉[𝐾𝑣 ] =
𝑉[𝐾𝑣 ] =

𝑆𝑢𝑝𝑣2
2
. (𝐸 [(𝑁𝑣 . (𝑙 + 𝐼𝑙 )) ] − (𝐸[𝑁𝑣 . (𝑙 + 𝐼𝑙 )])2 )
𝑚𝑣2

𝑆𝑢𝑝𝑣2
2
. ((𝐸[𝑁𝑣2 ]. 𝐸[(𝑙 + 𝐼𝑙 )2 ]) − ([𝐸[𝑁𝑣 ]] . [𝐸[(𝑙 + 𝐼𝑙 )] ]2 ))
𝑚𝑣2

As
𝐸[𝑁𝑣2 ] = 𝑉[𝑁𝑣 ] + 𝐸[𝑁𝑣 ]2 and 𝐸[(𝑙 + 𝐼𝑙 )2 ] = 𝑉[𝑙 + 𝐼𝑙 ] + 𝐸[𝑙 + 𝐼𝑙 ]2 ,
then
𝑉[𝐾𝑣 ] =

𝑆𝑢𝑝𝑣2
2
. ((𝑉[𝑁𝑣 ] + 𝐸[𝑁𝑣 ]2 ). (𝑉[𝑙 + 𝐼𝑙 ] + 𝐸[𝑙 + 𝐼𝑙 ]2 ) − ([𝐸[𝑁𝑣 ]] . [𝐸[(𝑙 + 𝐼𝑙 )] ]2 )) .
2
𝑚𝑣

Expanding the terms
𝑉[𝐾𝑣 ] =

𝑆𝑢𝑝𝑣2
. (𝑉[𝑁𝑣 ]. 𝑉[𝑙 + 𝐼𝑙 ] + 𝑉[𝑁𝑣 ]. 𝐸[𝑙 + 𝐼𝑙 ]2 + 𝐸[𝑁𝑣 ]2 . 𝑉[𝑙 + 𝐼𝑙 ] + 𝐸[𝑁𝑣 ]2 . 𝐸[𝑙 + 𝐼𝑙 ]2
𝑚𝑣2
2

− ([𝐸[𝑁𝑣 ]] . [𝐸[(𝑙 + 𝐼𝑙 )] ]2 )),
since 𝑉[𝑙 + 𝐼𝑙 ] = V[𝐼𝑙 ] 𝑎𝑛𝑑 𝐸[𝑙 + 𝐼𝑙 ] = 𝑙 + 𝐸 [𝐼𝑙 ], then
𝑉[𝐾𝑣 ] =

𝑆𝑢𝑝𝑣2
. (𝑉[𝑁𝑣 ]. 𝑉[𝐼𝑙 ] + 𝑉[𝑁𝑣 ]. 𝐸[𝑙 + 𝐼𝑙 ]2 + 𝐸[𝑁𝑣 ]2 . 𝑉[𝐼𝑙 ])
𝑚𝑣2

(8)

In the second step, we determine the expected antigen lead-time demand and its variance as a consequence of the
vaccine supply shortages. Thus, the expected lead-time demand of each antigen corresponds to the sum of the supply
shortages across all the vaccines containing the given antigen. Similarly, the variance of the antigen lead-time demand
is the sum of the variances of all the vaccines supplying the given antigen.
𝐸[𝐷𝑎 ] = ∑ 𝐸[𝐾𝑣 ]

∀𝑎 ∈𝐴

(9)

𝑣 𝜖 𝑉𝑎

𝑉[𝐷𝑎 ] = ∑ 𝑉[𝐾𝑣 ]

∀𝑎 ∈𝐴

(10)

𝑣 𝜖 𝑉𝑎
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Finally, in the third step, we determine the expected lead-time demand and its variance for vaccines containing
antigens similar to those of the vaccines facing supply interruption. Thus, the vaccine expected lead-time demand and
its variance are a function of the antigen lead-time demand and variance.
Since more than one vaccine supplies a given antigen, we estimate 𝜑𝑣𝑎 , the fraction of antigen 𝑎 ∈ 𝐴 demand supplied
by vaccine 𝑣 ∈ 𝑉, which is shown in (3).
When a vaccine 𝑣 supplies multiple antigens, we determine the fraction of expected antigen demand to be supplied
by the given vaccine for each antigen contained in that vaccine. Let 𝑎 be the antigen for which the vaccine 𝑣 needs to
supply the highest expected number of doses. It is represented by the following expression:
𝑎 = Arg(max{𝜑𝑣𝑎1 . 𝐸[𝐷𝑎1 ] | 𝑎1 𝜖 𝐴𝑣 }) .
𝑎1

Then the expected vaccine lead-time demand 𝐸[𝐷𝑣 ] and its variance 𝑉[𝐷𝑣 ] must account for largest antigen shortage,
𝐸[𝐷𝑣 ] = 𝜑𝑣𝑎 . 𝐸[𝐷𝑎 ]

(11)

2
𝑉[𝐷𝑣 ] = 𝜑𝑣𝑎
. 𝑉[𝐷𝑎 ]

(12)

Now, we determine the safety stock that ensures a desired service level 𝛼. By its definition the probability of having
no stockouts during interruption lead-time is equal to 𝛼%,
𝑃(𝐷𝑣 ≤ 𝑅𝑣 ) = 𝛼 = Probability of no stockout during leadtime ,

(13)

where inventory re-order level corresponds to
𝑅𝑣 = 𝐸[𝐷𝑣 ] + 𝑆𝑆𝑣 where 𝑆𝑆𝑣 = Safety Stock of vaccine

.

(14)

Subtracting 𝐸[𝐷𝑣 ] from both sides of inequality in (13) and dividing by 𝜎𝐷𝑣 obtained from (12) we obtain

𝑃(

𝐷𝑣 − 𝐸[𝐷𝑣 ]
𝑅𝑣 − 𝐸[𝐷𝑣 ]
≤
) = 𝛼.
𝜎𝐷𝑣
𝜎𝐷𝑣

By the central limit theorem and the definition of a standardized normal variable,

𝑃 (𝑍 ≤

𝑆𝑆𝑣
)≤ 𝛼
𝜎𝐷𝑣

𝑆𝑆𝑣 = 𝑍𝛼 √𝑉[𝐷𝑣 ]
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Substituting 𝑉[𝐷𝑣 ] from (12)
2 . 𝑉[𝐷 ]
𝑆𝑆𝑣 = 𝑍𝛼 √𝜑𝑣𝑎
𝑎

(15)

(15) corresponds to the safety stock that will ensure 𝛼% service level during the interruption. Similarly, we can define
the re-order level at which orders must be placed when the system does not face supply interruption,
2 . 𝑉[𝐷 ]
𝑅𝑣 = 𝜑𝑣𝑎 . 𝐸[𝐷𝑎 ] + 𝑍𝛼 √𝜑𝑣𝑎
𝑎

5. Model Validation
To validate the tractable safety stock model as shown in (15), we will compare its results with the simulation results
for the same experimental scenarios performed in the simulation study. To perform this comparison, we will use
distributions and input parameters similar to those we used for the simulated experimental scenario.
We follow a truncated normal distribution for the interruption length, as used in the simulation study. From the mean
and standard deviation of normal distribution denoted by 𝑁(𝜇𝐼𝑙 , 𝜎𝐼𝑙 ) we determine the mean and standard deviation of
truncated normal distribution 𝑁𝑇 (𝜇𝑡𝐼𝑙 , 𝜎𝑡𝐼𝑙 ) by using following equations:

𝜇𝑡𝐼𝑙

𝜎𝑡𝐼2 𝑙

−𝜇
𝜙( 𝐼𝑙⁄𝜎𝐼 )
𝑙
= 𝜇𝐼𝑙 + 𝜎𝐼𝑙 .
−𝜇𝐼𝑙
1− 𝛷(
⁄𝜎𝐼 )
𝑙

−𝜇𝐼𝑙
2
−𝜇
−𝜇𝐼𝑙
. 𝜙( 𝐼𝑙⁄𝜎𝐼 )
𝜙(
)
⁄
𝜎
𝜎
𝑙
𝐼𝑙
⁄
= 𝜎𝐼2𝑙 . (1 + ( 𝐼𝑙
) −(
⁄
) ),
−𝜇
−𝜇
1 − 𝛷 ( 𝐼𝑙⁄𝜎𝐼 )
1 − 𝛷 ( 𝐼𝑙⁄𝜎𝐼 )
𝑙

𝑙

where
𝜙( ) : Probability Density Function (p. d. f) of normal distribution
𝛷( ): Cumulative Density Function (c. d. f) of normal distribution
Thus, if we substitute the mean and variance of 𝐼𝑙 following truncated normal distribution and 𝑁𝑣 following binomial
distribution, the expressions (7) and (8) for 𝐸[𝐾𝑣 ] and 𝑉[𝐾𝑣 ] are given by
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𝐸[𝐾𝑣 ] =

𝑉[𝐾𝑣 ] =

𝑆𝑢𝑝𝑣
. 𝑚𝑣 𝑝𝑣 . (𝑙 + 𝜇𝑡𝐼𝑙 )
𝑚𝑣

𝑆𝑢𝑝𝑣2
2
{𝑚𝑣 𝑝𝑣 (1 − 𝑝𝑣 ). 𝜎𝑡𝐼2 𝑙 + 𝑚𝑣 𝑝𝑣 (1 − 𝑝𝑣 ). (𝑙 + 𝜇𝑡𝐼𝑙 ) + (𝑚𝑣 𝑝𝑣 )2 . 𝜎𝑡𝐼2 𝑙 } .
2
𝑚𝑣

Then, the expected antigen lead-time demand and variance remain the same as (9) and (10)
𝐸[𝐷𝑎 ] = ∑ 𝐸[𝐾𝑣 ]
𝑣 𝜖 𝑉𝑎

𝑉[𝐷𝑎 ] = ∑ 𝑉[𝐾𝑣 ] .
𝑣 𝜖 𝑉𝑎

The expected vaccine lead-time demand and variance are as given by (11) and (12)
𝐸[𝐷𝑣 ] = 𝜑𝑣𝑎 . 𝐸[𝐷𝑎 ]
2
𝑉[𝐷𝑣 ] = 𝜑𝑣𝑎
. 𝑉[𝐷𝑎 ] ,

where
𝑎 = Arg(max{𝜑𝑣𝑎1 . 𝐸[𝐷𝑎1 ] | 𝑎1 𝜖 𝐴𝑣 }) .
𝑎1

We use the above expressions and obtain the stockpile level for the shortage scenarios described in experiment 1 (refer
to section 4.1.2.1) without considering stockpiling policy as one of the experimental factors since it has no effect on
the vaccine shortage level, as seen in the simulation study. Now, from the simulation study, we obtain the expected
vaccine shortages and their variance for each experimental scenario of experiment 1. The expected vaccine shortage
from the simulation can also be termed as the expected vaccine lead-time demand during the interruption, and thus
the computed shortage variance can be used in expression (15) to obtain the safety stock of vaccines for those
simulated experimental scenarios. Thus, we have the expected vaccine lead-time demand and stockpile levels from
two different approaches, and we compare them using a 2-sample t-test. Table 9 summarizes the results of the 2sample t-test for each vaccine. The null and alternate hypotheses that we want to test are as follows:
𝐻05 : Mean of [𝐸[𝐷𝑣 ]]𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 = Mean of [𝐸[𝐷𝑣 ]]𝑖𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑚𝑜𝑑𝑒𝑙
𝐻𝑎5 : Mean of [𝐸[𝐷𝑣 ]]𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 ≠ Mean of [𝐸[𝐷𝑣 ]]𝑖𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑚𝑜𝑑𝑒𝑙
𝐻06 : Mean of [𝐸[𝑆𝑆𝑣 ]]𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 = Mean of [𝐸[𝑆𝑆𝑣 ]]𝑖𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑚𝑜𝑑𝑒𝑙
𝐻𝑎6 : Mean of [𝐸[𝑆𝑆𝑣 ]]𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 ≠ Mean of [𝐸[𝑆𝑆𝑣 ]]𝑖𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 𝑚𝑜𝑑𝑒𝑙
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Table 9: Summary of 2-sample t-test comparison of expected lead-time demand and safety stock of vaccines
Expected Lead-time Demand (Million Doses)
Vaccine

Safety Stock (Million Doses)

Tractable
Confidence
P- Tractable
Confidence
PSimulation Difference
Simulation Difference
Model
Interval
value Model
Interval
value

DTwP

3.6

3.67

0.07

(-0.44, 0.30) 0.710

6.64

6.96

-0.322

(-0.99, 0.35) 0.345

Penta

4.74

5.97

-1.229

(-1.65, -0.81) 0.000

8.43

9.46

-1.021

(-1.78, -0.27) 0.008

Hib

1.92

1.95

-0.032

(-0.26, 0.19) 0.780

3.39

3.56

-0.168

(-0.51, 0.18) 0.338

HepB

1.92

1.95

-0.028

(-0.25, 0.19) 0.803

3.39

3.58

-0.19

(-0.54, 0.15) 0.279

From the statistical comparison shown in Table 9, we can see that the expected lead-time demand and the safety stock
levels of all the three vaccines, DTwP, Hib, and HepB, match very well with the simulation results. However, the
penta vaccine’s expected lead-time demand and the safety stock from the tractable model seem underestimated. We
plotted a scatterplot of the safety stock levels from the simulation on X-axis and the tractable model on the Y-axis
with a line of equality at a 45-degree angle (refer to Figure 8) for the same experimental scenarios. It can be seen that
the stockpile levels from the tractable model and the simulation study are aligned along the line of equality for all
three vaccines. However, for the penta vaccine, the stockpile levels deviate away from the line of equality, showing
the differences in the tractable model and the simulation results. The underestimation of the stockpile levels from the
tractable model is observed only for combination vaccines, which means an evaluation of the vaccine’s expected leadtime demand and its variance (refer to (11) and (12)) when the vaccine is supplying more than one antigen, provides
lower values than the simulation results. The deviation from the equality line is smaller when the stockpile levels are
low; however, the deviation seems to be amplified as the stockpile levels are increased.
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Figure 8: Scatterplot with line of equality—comparing stockpile levels from simulation study and tractable model
Applying the tractable safety stock model to the same scenarios used in experiments 1, 2, and 3 from our simulation
study, we compare the stockpile levels for different types of vaccine mixes (refer to sections 4.1.2.1, 4.1.2.2, and
4.1.2.3). We evaluate the safety stock levels for having both combination and monovalent vaccines together in the
safety stock, only monovalent vaccines, and only combination vaccines, respectively. Figures 9 shows the boxplot of
the stockpile levels and the cost of purchasing such stockpiles for each type of the vaccine mix. Boxplot of stockpile
levels illustrates that having only monovalent vaccines results in the highest stockpile levels as compared with the
other two vaccine mixes. Therefore, it is preferable not to have stockpiles that constitute only monovalent vaccines
since it puts excessive pressure on the cold-chain needs. Additionally, with the price of vaccines used in this study,
the purchasing cost is highest for the monovalent vaccine stockpiles. Thus, monovalent vaccine stockpiles are also not
an adequate choice when we look at things from the cost perspective.
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Figure 9: Stockpile levels and stockpile cost comparison for different vaccine mixes
The purchasing costs of vaccines in stockpiles with only combination vaccines and with a mix of combination and
monovalent vaccines are statistically the same. The results of the 2-sample t-test in Table 10 shows that the differences
in stockpile levels and cost are statistically insignificant for stockpiles with only combination vaccines and stockpiles
with a mix of combination and monovalent vaccines.
Table 10: 2-sample t-test results for stockpile levels and stockpile cost

Stockpile Levels
(M Doses)
Stockpile Cost
(M USD)

Comb

Comb_Mono

Difference

Confidence
Interval

P-values

18.68

21.86

-3.17

(-12.92, 6.58)

0.468

35.69

32.14

3.55

(-15.06, 22.17)

0.665

To evaluate the price conditions under which having only monovalent vaccines in the stockpile would be a preferred
option, we performed a cost analysis by varying the price of the monovalent vaccine Hib as USD 0.64 per dose instead
of USD 4.00. The graphical analysis of the stockpile cost with the new price for the Hib vaccine is shown in Figure
10. The stockpile cost of monovalent vaccines became as attractive as those of the other two safety stock
configurations. However, as we observed in Figure 9, the stockpile quantity for monovalent vaccines is rather high.
The stockpile levels with only combination vaccines and with a mix of combination and monovalent vaccine are
similar, but under the revised price conditions of monovalent vaccines, the cost of a stockpile with a mix of
combination and monovalent vaccines is much lower than that of a stockpile with only combination vaccines.
Therefore, it is preferred to have a stockpile of a mix of combination and monovalent vaccines to facilitate lower
stockpile levels and lower cost investment.
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Figure 10: Revised stockpile cost for each type of vaccine mix with Hib price as USD 0.64

6. Conclusion
The tractable safety stock model developed in this study can be used to determine the stockpile levels for any of the
combination or monovalent vaccines with multiple suppliers, varying likelihoods of supply interruption, and random
interruption lengths.
Three out of the four key factors considered in the study affect the safety stock levels significantly. The stockpile level
decreases with an increase in the number of suppliers of the vaccine. However, it increases when the probability of
interruption at the suppliers or the mean interruption length increases. The stockpile levels are not affected when we
switch from the policy to stockpile risky vaccines to the policy to stockpile robust vaccines.
The analysis of stockpile quantity and the stockpile purchasing cost for different types of vaccine mixes shows that it
is preferred to have stockpiles with a mix of combination and monovalent vaccines since this results in lower stockpile
levels as compared to having only monovalent vaccine stockpiles and lower purchasing costs as compared to having
only combination vaccine stockpiles.
The tractable inventory model allows one to perform a sensitivity analysis with ease. Thus, this study can be extended
to perform a sensitivity analysis to understand the range of the input parameters for which the stockpile levels would
remain unchanged.
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Appendix:
Table A: List of examples for pediatric vaccine shortages in US
Duration
Vaccine
Start year
Reason
(months)
Tetanus and Diphtheria
November,
19
Change
in
manufacturing
process,
toxoids/Tetanus Toxoid (Td/TT)
2000
manufacturer leaving market
Diphtheria and Tetanus toxoids
17
Change
in
manufacturing
process,
and acellular Pertussis vaccine March, 2001
manufacturer leaving market
(DTaP)
Measles, Mumps and Rubella October,
10
Change in manufacturing process
vaccine (MMR)
2001
October,
11
Varicella (VAR)
Change in manufacturing process
2001
Pneumococcal Conjugate
22
August, 2001
Manufacturer upgrading filling line
Vaccine (PCV)
Pneumococcal Conjugate
December,
10
Manufacturer upgrading filling line
Vaccine (PCV)
2003
Pneumococcal Conjugate
February,
7
Vaccine (PCV)
2004
Meningococcal conjugate
3
June, 2005
High Demand
vaccine (MCV4)
Meningococcal conjugate
3
June, 2006
High Demand
vaccine (MCV4)
9
Hepatitis A
July, 2007
Haemophilus Influenzae type b
vaccine (Hib)
Diptheria and Tetanus toxoids and
acellular Pertusis vaccine (DTaP)
Hepatitis A and varicella

December,
2007
April, 2012
January 2016

19
18

Manufacturer recalled lots of vaccines both
monovalent and combination doses
Manufacturer
cannot
meet
demand
requirements
Payment problems

Table B: [24], [25]Low Income and Lower Middle Income countries of WHO Africa region
Sr No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Countries
Benin
Burkina Faso
Burundi
Cabo Verde
Cameroon
Chad
Côte d'Ivoire
Eritrea
Ethiopia
Ghana
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
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18
19
20
21
22
23
24
25
26
27
28

Mauritania
Mozambique
Rwanda
Senegal
Sierra Leone
South Sudan
Swaziland
Togo
Uganda
Zambia
Zimbabwe

Percentage of Countries by Region
120
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40
20

12
4
14
6

18
5
18
5

14
2
17

12
4
18

12

7

39

38

38
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18

19

2013

2012

2011

2010

17
7
7
6

32

47
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Figure A1: Percentage of countries by WHO region facing stockout (2010-2014)

Percentage of Countries by Income Group
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Figure A2: Percentage of countries by Income group facing the vaccine shortages
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Figure A3: Experiment 1- Interaction effects of factors on total expected shortage levels

Figure A4: Experiment 1 - Interaction effects of factors on individual vaccine expected shortage levels

36

Figure A5: Experiment 1- Interaction effects of factors on total shortage variance

Figure A6: Experiment 1- Interaction effects of factors on individual vaccine shortage variance
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